A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
| dc.contributor.author | Smith, David B | |
| dc.contributor.author | Howell, Anthony | |
| dc.date.accessioned | 2010-10-20T10:18:37Z | |
| dc.date.available | 2010-10-20T10:18:37Z | |
| dc.date.issued | 1987-04 | |
| dc.identifier.citation | A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer. 1987, 23 (4):391-4 Eur J Cancer Clin Oncol | en |
| dc.identifier.issn | 0277-5379 | |
| dc.identifier.pmid | 3475204 | |
| dc.identifier.doi | 10.1016/0277-5379(87)90375-0 | |
| dc.identifier.uri | http://hdl.handle.net/10541/113517 | |
| dc.description.abstract | Thirty-eight patients with advanced breast cancer were treated with oral 4-demethoxydaunorubicin in a continuous weekly schedule at a dose of 15 mg/m2/week. Subjective toxicity consisted of mild nausea (grade 1) in 52% with more severe GI side effects (grade 2) in 15%. Three patients developed grade 1 alopecia and there were no episodes of cardiac failure. Significant neutropenia (grade 2/3) only occurred in patients with marrow involvement or widespread bone disease. There was one CR and 5 PRs, an overall response rate of 15.7% (95% confidence limits 6-31%). In addition 6 patients had disease stabilization for at least 6 months. Fourteen patients progressing on 4-demethoxydaunorubicin have received adriamycin 60 mg/m2 21 days. There have been 5 PRs in this group indicating possible non-cross-resistance between these two agents. | |
| dc.language.iso | en | en |
| dc.subject | Breast Cancer | en |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Antibiotics, Antineoplastic | |
| dc.subject.mesh | Breast Neoplasms | |
| dc.subject.mesh | Daunorubicin | |
| dc.subject.mesh | Doxorubicin | |
| dc.subject.mesh | Drug Evaluation | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Idarubicin | |
| dc.subject.mesh | Middle Aged | |
| dc.title | A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer. | en |
| dc.type | Article | en |
| dc.identifier.journal | European Journal of Cancer & Clinical Oncology | en |
| html.description.abstract | Thirty-eight patients with advanced breast cancer were treated with oral 4-demethoxydaunorubicin in a continuous weekly schedule at a dose of 15 mg/m2/week. Subjective toxicity consisted of mild nausea (grade 1) in 52% with more severe GI side effects (grade 2) in 15%. Three patients developed grade 1 alopecia and there were no episodes of cardiac failure. Significant neutropenia (grade 2/3) only occurred in patients with marrow involvement or widespread bone disease. There was one CR and 5 PRs, an overall response rate of 15.7% (95% confidence limits 6-31%). In addition 6 patients had disease stabilization for at least 6 months. Fourteen patients progressing on 4-demethoxydaunorubicin have received adriamycin 60 mg/m2 21 days. There have been 5 PRs in this group indicating possible non-cross-resistance between these two agents. |